TRZ-2: Research Overview

Full name

Modified 39-residue dual incretin receptor agonist (research designation; corresponds to the analytical reference compound also referenced in published literature as Tirzepatide)

Molecular formula

C225H348N48O68

Molecular weight

4813.45 g/mol

Sequence / class

39-residue modified linear peptide with C20 fatty diacid side chain and Aib substitutions

Receptor targets

Dual engagement of GLP-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), both class B G-protein-coupled receptors coupled to Gαs

Research classification

Dual incretin receptor research peptide. Note: the parent reference compound in published literature carries FDA approval in its approved pharmaceutical form for specified clinical indications; the research-grade lyophilized reagent supplied here is for in vitro analytical use only

PubChem CID

156588324

TRZ-2 is the PūrTONIX research designation for a 39-residue dual-incretin-receptor peptide whose analytical reference identity in published literature corresponds to the molecule commonly referenced as Tirzepatide. The compound carries Aib substitutions that confer stability against dipeptidyl-peptidase-4 cleavage and a C20 fatty diacid side chain that supports albumin binding and extended in vitro functional half-life. The molecular formula is C225H348N48O68 with a calculated mass near 4813 daltons.

Published literature classifies the parent reference compound as a dual incretin receptor agonist. It engages both the GLP-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR), each a class B G-protein-coupled receptor coupled to Gαs with downstream cAMP accumulation, PKA cascade activation, and characterized β-cell signaling biochemistry in in vitro reporter systems.

Research published in the peer-reviewed literature has used the parent compound as an analytical reference in dual-receptor pharmacology studies. The extended in vitro functional half-life relative to native incretin peptides allows time-resolved signaling readouts to resolve cleanly across multi-hour cellular assay windows, which has made the molecule a useful benchmark when characterizing newer multi-receptor research peptides.

The research-grade lyophilized form supplied as TRZ-2 is intended strictly for in vitro analytical use. The approved pharmaceutical formulation of the parent reference compound carries FDA approval for specified clinical indications; the research reagent supplied here is not formulated, sterilized, or characterized for human or veterinary administration and is sold solely as a laboratory analytical input.

Structure reference: Public domain chemical databases (PubChem CID 156588324).

Published in vitro applications of the parent reference compound include reporter assays in HEK293 cell lines stably expressing GLP-1R, GIPR, and dual-receptor cell systems. Investigators have used the peptide to characterize EC50 values and signaling-cascade ratios across the two receptor classes under matched analytical conditions, with cAMP accumulation as the standard proximal readout.

Receptor-binding studies indicate that dual-receptor engagement recruits complementary intracellular signaling cascades that mono-agonism does not access cleanly in in vitro assays. Published research has compared the parent compound against GLP-1-only and GIP-only reference agonists in matched cellular reporter systems to deconvolute contributions from each receptor axis.

Comparative in vitro panels that include the dual-receptor compound, GLP-1 mono-agonists such as semaglutide, and tri-receptor research peptides allow investigators to characterize how receptor selectivity profiles influence downstream signaling biochemistry under reproducible analytical conditions.

• [1]A study published in Molecular Metabolism (2018) examined dual GIP/GLP-1 receptor agonist biochemistry in publicly available in vitro reporter systems with comparative analytical readouts.
• [2]A study published in Cell Metabolism (2019) investigated dual-incretin-receptor signaling kinetics in cellular models using long-acting research peptides.
• [3]A study published in Diabetes (2020) reviewed publicly available literature on dual-receptor incretin research peptides and their in vitro reporter pharmacology.

The above represents a non-exhaustive summary of publicly available research. PūrTONIX does not endorse, validate, or make claims based on any referenced study.

Published chemical property data indicate that the parent reference compound is soluble in mildly alkaline aqueous buffer and in phosphate-buffered saline at standard assay concentrations. The lyophilized peptide is stored at -20°C under inert atmosphere with reconstituted stocks held in single-use aliquots at 2-8°C for short-term in vitro use.

Reconstitution in PBS or in assay-matched buffer is standard for in vitro dual-receptor pharmacology work. Analytical characterization commonly includes reverse-phase HPLC purity analysis, electrospray mass spectrometry confirming the 39-residue sequence with intact Aib substitutions and C20 fatty diacid side chain, and residual solvent screening per ICH Q3C.

Handling recommendations are based on published chemical property data and are intended for qualified laboratory personnel only.

Dual-receptor reporter assays are sensitive to deletion peptides and to incomplete fatty-acid side-chain attachment. Material characterized for high chromatographic purity with documented mass-spectral identity provide the analytical baseline for reproducible in vitro comparative pharmacology research.